MEI Pharma, Inc. (MEIP)
| Market Cap | 376.97M |
| Revenue (ttm) | 40.92M |
| Net Income (ttm) | -63.34M |
| Shares Out | 112.56M |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $3.35 |
| Previous Close | $3.31 |
| Change ($) | 0.04 |
| Change (%) | 1.21% |
| Day's Open | 3.31 |
| Day's Range | 3.24 - 3.36 |
| Day's Volume | 716,828 |
| 52-Week Range | 2.29 - 4.58 |
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -33.33% and -46.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, May 6, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended Ma...
SAN DIEGO, April 30, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the retirement of Ro...
MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, April 13, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, and Kyowa Kirin Co., Ltd. (TSE:415...
SAN DIEGO, April 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced preclinical data demonstrati...
SAN DIEGO, April 5, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the 20th...
SAN DIEGO, March 10, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the abstract, Vorucicli...
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of -46.67% and 340.09%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended D...
MEI Pharma, Inc. (MEIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Jan. 4, 2021 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Phase 1b trial arm ex...
MEIP's pracinostat is a disaster; but zandelisib has always been its core asset. If all goes well, zandelisib may be in the market for r/r FL by 2021.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investiga...
SAN DIEGO, Nov. 10, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended ...
SAN DIEGO--(BUSINESS WIRE)---- $MEIP #ClassAction--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against th...
NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020,...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP) and ce...
Los Angeles, California--(Newsfile Corp. - October 9, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...
New York, New York--(Newsfile Corp. - October 8, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017...
Los Angeles, California--(Newsfile Corp. - October 8, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...
Los Angeles, California--(Newsfile Corp. - October 7, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...
Los Angeles, California--(Newsfile Corp. - October 6, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...
Los Angeles, California--(Newsfile Corp. - October 5, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...
New York, New York--(Newsfile Corp. - October 2, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017...
Los Angeles, California--(Newsfile Corp. - October 2, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc. ...
TOKYO and SAN DIEGO, Oct. 2, 2020 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company creating innovative medical solutions utilizing the latest bio...
NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 202...
New York, New York--(Newsfile Corp. - September 25, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in MEI Pharma, Inc. ("MEI Pharma" or the "Company") (NASDAQ:M...
New York, New York--(Newsfile Corp. - September 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2...
New York, New York--(Newsfile Corp. - September 18, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.
SAN DIEGO, Sept. 15, 2020 /PRNewswire/ -- MEI Pharma, Inc.
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc.
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.
New York, New York--(Newsfile Corp. - September 12, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (...
SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- MEI Pharma, Inc.
New York, New York--(Newsfile Corp. - September 4, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
SAN DIEGO, Sept. 4, 2020 /PRNewswire/ -- MEI Pharma, Inc.
NEW YORK, Aug. 27, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against MEI Pharma, Inc.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc. (NASDAQ: MEIP) between August 2, 2017 and July 1, 2020, inclusive (...
NEW YORK, Aug. 21, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of MEI Pharma, Inc.
New York, New York--(Newsfile Corp. - August 19, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MEI Pharma, Inc.
NEW YORK, Aug. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of MEI Pharma, Inc.
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against MEI Pharma, Inc. ("MEI Pharma" or "the Company") (NASDAQ: MEIP) and ce...
SAN DIEGO--(BUSINESS WIRE)---- $MEIP #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of MEI Pharma, Inc. (NASDAQ: MEIP) filed a class action complaint against the Compan...
LOS ANGELES--(BUSINESS WIRE)---- $MEIP #MEIP--SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc.
Los Angeles, California--(Newsfile Corp. - August 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against MEI Pharma, Inc.
About MEIP
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It a... [Read more...]
| Industry Biotechnology | IPO Date Dec 19, 2003 |
| CEO Daniel Gold | Employees 51 |
| Stock Exchange NASDAQ | Ticker Symbol MEIP |
Financial Performance
In 2020, MEI Pharma's revenue was $28.91 million, an increase of 488.26% compared to the previous year's $4.92 million. Losses were -$46.02 million, 173.6% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for MEI Pharma stock is "Strong Buy." The 12-month stock price forecast is 9.67, which is an increase of 188.66% from the latest price.